EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Obesity care in the glucagon-like peptide-1 era, part 1: Delays, barriers, and opportunities to improve access and patient engagement

Jamy Ard, Joseph Grimsby, Joseph Nadglowski, Rosemarie Sellati

Obesity Pillars · 2026-11 · 100356

DOI: 10.1016/j.obpill.2026.100356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Pillars, 2026-11. Verfasst von Jamy Ard und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The obesity care journey is often characterized by delayed engagement, fragmented care, and limited treatment expectations. This study aimed to characterize the contemporary obesity care journey stages, reported factors associated with treatment initiation, barriers, and treatment-choice processes.

Methods

This was a multimethod, cross-sectional study integrating 3 sources: (1) healthcare provider (HCP)–reported data from 640 HCPs and 1,695 patient record forms (PRFs) collected in 2023 and 2024; (2) semistructured interviews with 16 adults living with obesity and 16 HCPs; and (3) social-listening analyses of publicly available online discussions. Quantitative data were analyzed descriptively; qualitative findings were synthesized manually, and social-listening data were analyzed using natural language processing/artificial intelligence methods and manual review. Findings were integrated using a triangulation approach.

Results

Among 440 evaluable fourth-quarter (Q4) 2023 PRFs, the mean HCP-recorded interval between documented experience of weight or weight-related condition(s) and the first weight management discussion was 7.5 years; 65% of all 720 PRFs were self-referred to the current HCP. Qualitative findings described repeated unsuccessful weight loss attempts, stigma, self-blame, and limited treatment expectations before widespread availability of glucagon-like peptide-1 (GLP-1)–based therapies, and greater treatment awareness and individual-initiated discussions later. Among 506 PRFs for individuals receiving prescription medication for weight loss, HCPs classified 298 treatment choices (59%) as joint individual–HCP decisions. Insurance coverage, affordability, and access barriers were reported to constrain treatment choice.

Conclusions

This Part 1 manuscript describes delays, barriers, and opportunities to improve access and engagement across the obesity care journey; the companion Part 2 manuscript examines clinical, patient, and system factors shaping treatment decision-making. Awareness of GLP-1–based therapies was described alongside treatment seeking and treatment discussions, whereas structural barriers were reported to constrain treatment initiation and continuation. Clinical outcomes and long-term treatment persistence were not evaluated.

Zitieren

APA

Ard, J., Grimsby, J., Nadglowski, J., & Sellati, R. (2026). Obesity care in the glucagon-like peptide-1 era, part 1: Delays, barriers, and opportunities to improve access and patient engagement. Obesity Pillars, 100356. https://doi.org/10.1016/j.obpill.2026.100356

Vancouver

Ard J, Grimsby J, Nadglowski J, Sellati R. Obesity care in the glucagon-like peptide-1 era, part 1: Delays, barriers, and opportunities to improve access and patient engagement. Obesity Pillars. 2026:100356. doi:10.1016/j.obpill.2026.100356

BibTeX
@article{Ard2026,
  author = {Ard, Jamy and Grimsby, Joseph and Nadglowski, Joseph and Sellati, Rosemarie},
  title = {Obesity care in the glucagon-like peptide-1 era, part 1: Delays, barriers, and opportunities to improve access and patient engagement},
  journal = {Obesity Pillars},
  year = {2026},
  pages = {100356},
  doi = {10.1016/j.obpill.2026.100356}
}
Kostenlos starten →